Original Articles Korean Circulation J 2000;309:1107-1116 한국인에서관상동맥질환에대한만성감염및염증의역할 김계훈 1 정명호 2 신종희 2 주신배 1 김원 1 이승욱 1 김건형 1 김남호 1 조장현 1 박종철 1 안영근 1 나국주 1 조정관 2 안병희 2 박종춘 2 강정채 1 The Role of Chronic Infection and Inflammation in Korean Patients with Coronary Artery Disease Kye Hun Kim, MD 1, Myung Ho Jeong, MD 2, Jong Hee Shin, MD 2, Shin Bae Joo, MD 1, Weon Kim, MD 1, Seung Uk Lee, MD 1, Kun Hyung Kim, MD 1, Nam Ho Kim, MD 1, Jang Hyun Cho, MD 1, Jong Choel Park, MD 1, Kook Joo Na, MD 1, Young Keun Ahn, MD 1, Jeong Gwan Cho, MD 1, Byoung Hee Ahn, MD 2, Jong Chun Park, MD 2 and Jung Chaee Kang, MD 2 1 Department of Internal Medicine, The Heart Center, Chonnam National University Hospital, Seoul, 2 The Research Institute of Medical Sciences, Kwangju, Korea ABSTRACT BackgroundChronic infections, including Chlamydia pneumoniae, cytomegalovirus and Helicobacter pylori may be one of the risk factors for coronary artery disease CAD. To document whether chronic infection may be associated with coronary artery disease, various inflammatory markers were analyzed in Korean patients with CAD. MethodsThe patients who underwent diagnostic coronary angiography CAG were divided into two groups according to the results of CAGthe patients with significant coronary lesions Group n126, MF9927, 58.79.7 years or the patients without coronary lesions Group n58, MF3028, 55.58.9 years. Serologic assays for the immunoglobulin G IgG titers to C. pneumoniae, CMV, H. pylori, and for inflammatory markers, including erythrocyte sedimentation rate ESR and C-reactive protein CRP were performed. ResultsThere were no significant differences in the seropositivity of three infections between two groups, but titer of IgG antibody against H. pylori was significantly higher in Group than that in Group 859.3342.2 vs. 474.2113.2 U/mL, p0.02. After adjustment for age, sex and other cardiovascular risk factors, high titer of IgG antibody aganist H. pylori was independently associated with coronary artery disease p0.05. CRP and ESR were significantly elevated in group 2.75.1 vs. 0.60.9 mg/dl, p0.003, 23.226.7 vs. 12.715 mm/hr, p0.006. Angiographic parameters were not related with the titer of infectious agents or inflammatory markers. The value of CRP was significantly different according to clinical severity 3.86.0 in acute myocardial infarction, 1.53.6 in unstable angina pectoris, and 0.40.3 mg/dl in stable angina pectoris, p0.01. The value of ESR was also significantly different according to clinical severity 29.030.2 in acute myocardial infarction, 17.119.0 in unstable angina pectoris, and 12.117.6 mm/hr in stable angina pectoris, p0.01. ConclusionsOur results 1107
suggest that high titer of IgG antibody against H. pylori may be associated with CAD, and inflammation may play a significant role in the pathogenesis of acute coronary syndromes. Korean Circulation J 2000;309: 1107-1116 KEY WORDSInfection Inflammation Coronary artery disease. 서론 대상환자 대상및방법 방법 1108 Korean Circulation J 2000;309:1107-1116
관상동맥조영술소견분석 통계방법 결과 임상적특징 감염과관상동맥질환 Table 1. Comparisons of clinical characteristics between Group with coronary artery disease and Group without coronary artery disease Group Group P value Number 126 58 Age yrs 58.79.7 55.58.9 0.05 Sex % 0.01 Male 99 78.5 30 51.7 Female 27 21.5 28 48.3 Clinical diagnosis % Acute myocardial 68 54.0 0 0.0 infarction Unstable angina 40 32.0 28 52.0 Stable angina 17 13.0 30 48.0 Silent ischemia 1 1.0 0 0.0 Risk factors % Smoking 78 62.0 19 33.0 0.01 Hypertension 45 35.7 17 29.3 NS Diabetes mellitus 30 23.8 11 19.0 NS Hypercholesterolemia 29 23.0 13 22.4 NS 1109
Table 2. Comparisons of seropositivity of infectious and inflammatory markers between Group with coronary artery disease and Group without coronary artery disease Group n126 Group n58 P value C. pneumoniae % 30 24 11 19 NS CMV % 126 100 58 100 NS H. pylori % 81 64 30 52 NS CRP% 66 52 8 14 0.001 ESR % 78 62 12 21 0.02 C. pneumoniaechlamydia pneumoniae, CMVCytomegalovirus, H. pylorihelicobacter pylori, CRPCreactive protein, ESRerythrocyte sedimentation rate. 염증지표와관상동맥질환 Fig. 1. Titer of IgG antibody against Helicobacter pylori was significantly higher in patients with coronary artery disease CAD than in normal control group. Table 3. Comparisons of seropositivity of infectious agents according to clinical diagnosis AMI n68 UAP n40 SAP P n17 value C. pneumoniae % 13 19 10 25 7 36 NS CMV % 68 100 40 100 17 100 NS H. pylori % 42 61 24 60 12 70 NS AMIacute myocardial infarction, UAPunstable angina pectoris, SAPstable angina pectoris, C. pneumoniaechlamydia pneumoniae, CMVCytomegalovirus, H. pylorihelicobacter pylori Fig. 2. The distribution of antibody titer aganist H. pylori between group with coronary artery disease and group without coronary artery disease. 1110 Korean Circulation J 2000;309:1107-1116
Table 4. Comparisons of serum concentrations of inflammatory markers between Group with coronary artery disease and Group without coronary artery disease Group n126 Group n58 P value CRP mg/dl 2.72 5.19 0.64 0.90 0.01 ESRmm/hr 23.2926.74 12.7815.05 0.01 Fibrinogenmg/dL 272.7982.55 253.0555.16 0.09 CRPC-reactive protein ESRerythrocyte sedimentation rate. Table 5. Angiographic characteristics of the patient group Target lesion Number % Left anterior descending artery 98 54 Right coronary artery 54 30 Left circumflex artery 28 16 Number of involved vessel One vessel disease 84 66 Two vessel disease 31 25 Three vessel disease 11 9 TIMI flow grade 0 24 13 8 5 99 55 49 27 AHA/ACC types A 4 2 B1 91 51 B2 58 32 C 27 15 TIMI Thrombolysis in myocardial infarction, AHA/ ACCAmerican Heart Association/American College of Cardiology 감염과염증지표 관상동맥조영술소견과비교 Fig. 3. The levels of C- reactive protein CRP and erythrocyte sedimentation rate ESR are significantly elevated in coronary artery disease CAD group than in normal control group. 1111
Fig. 4. There are significant differences in the level of C- reactive protein CRP according to clinical diagnosis 0.40.3 mg/dl in stable angina pectoris SAP, 1.5 3.6 mg/dl in unstable angina pectoris UAP, 3.86.0 mg/dl in acute myocardial infarction AMI. Fig. 5. There are significant differences in the level of erythrocyte sedimentation rate ESRaccording to clinical diagnosis12.117.6 mm/hr in stable angina pectoris SAP, 17.119.0 mm/hr in unstable angina pectoris UAP, 29.230.2 mm/hr in acute myocardial infarction AMI. 1112 고안 Korean Circulation J 2000;309:1107-1116
1113
연구배경 : 요 대상및방법 : 결과 : 약 결론 : 중심단어 REFERENCES 1) Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple risk factor assessment equations: A statement for healthcare professionals from the american heart association and the american college of cardiology. Circulation 1999;100: 1481-92. 2) Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994;331:468-9. 3) Van der Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44. 4) Libby P, Ridker PM. Novel inflammatory markers of coronary risk. Circulation 1999;100:1148-50. 5) Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24. 6) Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study. BMJ 1996;312:1061-5. 7) Oltrona L, Ardissino D, Merlini PA, Spinola A, Chiodo F, Pezzano A. C-reactive protein elevation and early outcome in patients with unstable angina pectoris. Am J Cardiol 1997;80:1002-6. 8) Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997; 96:4204-10. 9) Rebuzzi AG, Quaranta G, Liuzzo G, Caligiuri G, Lanza GA, Gallimore JR, et al. Incremental prognostic value of 1114 Korean Circulation J 2000;309:1107-1116
serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 1998;82:715-9. 10) Bogaty P, Robitaille NM, Solymoss S, Boyer L, Auger D, Labbe L, et al. Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compaired with longstanding uncomplicated stable angina. Am Heart J 1998;136:884-93. 11) Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998;32:35-41. 12) Morrow DA, Rifai N, Antman EM, Weiner DL, Mccabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI11A substudy. J Am Coll Cardiol 1998;31:1460-5. 13) Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 1998;279:1477-82. 14) Abdelmouttaleb I, Danchin N, Ilardo C, Aimone I, Angioi M, Lozniewski A, et al. C-reactive protein and coronay artery disease: Additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J 1999;137:346-51. 15) Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middleaged man: Results from the MONICA Monitoring trends and determinants in cardiovascular disease Ausburg cohort study, 1984 to 1992. Circulation 1999;99:237-42. 16) Fabricant CG, Fabricant J, Litrenta M, Minick C. Virusinduced atherosclerosis. J Exp Med 1978;148:335-40. 17) Menlick J, Dressman G, McCollum C, Petrie B, Burek J, DeBakey M. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983;2:644-7. 18) Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makera PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2:983-6. 19) Mendall MA, Groggin PM, Molineaux N, Levy J, Toosy T, Strachan D, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994;71: 437-9. 20) Ryan TJ, Bauman WB, Kennedy JW. Guidelines for percutaneous transluminal angioplasty: A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures Subcommittee on Percutaneous Transluminal Coronary Angioplasty. Circulation 1993; 88:2987. 21) Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, asprin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9. 22) Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990;161:618-25. 23) Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayton JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841-9. 24) Ramirez JA, and the Chlamydia pneumoniae/atherosclerosis Study Group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Int Med 1996;125:979-82. 25) Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerosis versus other forms of cardiovascular disease. J Am Coll Cardiol 1996;27: 1555-61. 26) Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998;31:827-32. 27) Gupta S, Leatham EW, Carrington M, Mendall MA, Ireson N, Tooze J, et al. The effect of azithromycin in postmyocardial infarction patients with elevated Chlamydia pneumoniae antibody titers. J Am Coll Cardiol 1997;29: 209A. 28) Gupta S, Leatham EW, Carrington M, Mendall MA, Kaski JC, Camm AJ, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7. 29) Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. Circulation 1999;99:1940-7. 30) Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. A prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarctions. Circulation 1999;99:1161-4. 31) Altman R, Rouvier J, Scazziota A, Absi RS, Gonzalez C. Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease. Clin Cardiol 1999;22:85-90. 32) Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-q-wave coronary syndromes: The final report of the ROXIS study. Eur Heart J 1999;20: 121-7. 33) Kim JK, Chung JY, Sung BY, Kim YC, Kim JH, Lee MS, et al. Positivity of Chlamydia pneumoniae antibody and it s significance in atherosclerosis. Korean Circulation J 1999;29:146-52. 34) Melnick J, Adam E, DeBakey M. Possible role of Cytomegalovirus in atherosclerosis. JAMA 1990;263:2204-7. 35) Adam E, Melnick JL, Probtsfield JL, Petrie BL, Burek J, Bailey KR, et al. High level of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987;2:291-3. 36) Hendrix M, Salimans M, Van Boven C, Bruggeman C. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade atherosclerosis. Am J Pathol 1990;136:23-8. 1115
37) Spier E, Modali R, Huang ES, Leon M, Shawl F, Finkel T, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265:391-4. 38) Zhou YF, Leon MB, Waclawiw MA, Pampa JJ, Yu ZX, Finkel T, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996;335:624-30. 39) Blum A, Giladi M, Weinberg M, Kaplan G, Pasternak H, Laniado S, et al. High anti-cytomegalovirus IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol 1998;81:866-8. 40) Adler SP, Hur JK, Wang JB, Vetrovec GW. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998;177:209-12. 41) Rothenbacher D, Hoffmeister A, Bode G, Wanner P, Koenig W, Brenner H. Cytomegalovirus infection and coronary heart disease: Results of a german casecontrol study. J Infect Dis 1999;179:690-2. 42) Manegold C, Alwazzeh M, Jablonowski H, Adams O, Medve M, Seidlitz B, et al. Prior cytomegalovirus infection and the risk of restenosis after percutaneous transluminal coronary balloon angioplasty. Circulation 1999;99:1290-4. 43) Howden CW. Clinical expression of Helicobacter pylori infection. Am J Med 1996;100:27-34. 44) Martinde-Argila C, Boixeda D, Canton R, Gisbert JP, Fuertes A. High seroprevalence of Helicobacter pylori infection in coronary heart disease. Lancet 1995;346:310. 45) Lip GH, Wise R, Beevers G. Association of Helicobacter pylori infection with coronary heart disease: Study shoes association between H. pylori infection and hypertension. Br Med J 1996;312:250-1. 46) Niemala S, Karttunen T, Korhonen T, Laara E, Karttunen R, Ikaheimo M, et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart 1996;75:573-5. 47) Strachan DP, Mendall MA, Carrington D, Butland BK, Yarnell JW, Sweetnam PM, et al. Relation of Helicobacter pylori infection to 13-year mortality and incident ischemic heart disease in the caerphilly prospective heart disease study. Circulation 1998;98:1286-90. 48) Khurshid A, Fenske T, Bajwa T, Bourgeois K, Bakil N. A prospective, controlled study of Helicobacter pylori seroprevalence in coronary artery disease. Am J Gastroenterol 1998;93:717-20. 49) Patel P, Carrington D, Strachan DP, Leatham EW, Goggin P, Northfield TC, et al. Fibrinogen: A link between chronic infection and coronary heart disease. Lancet 1994; 343:1634-5. 50) Kim YK, Kim DW. Seroepidemiology of human cytomegalovirus in healthy adults measured by means of the anticomplement immunofluorescence technique. Kor J Inf 1992;24:87-92. 51) Malaty HM, Kim JG, Kim SD, Graham DY. Prevalence of Helicobacter pylori infection in Korean children: Inverse relation to socioeconomic status despite a uniformly high prevalence in adults. Am J Epidemiol 1996;143: 257-62. 52) Yong DG, Lee HM, Kim HS, Lee JG, Lee YC. Clinical usefulness of Helicobacter pylori IgG Ab assay: Comparison of six commercial kits. Korean J Clin Pathol 1998; 18:447-61. 1116 Korean Circulation J 2000;309:1107-1116